

# 13/C
9 ND
7/30/02 1644

Docket Number DM-6909-B

CERTIFICATE OF MAILING

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being sent via United States Postal Service with sufficient First Class postage, on the date shown below, to the following address: United States Patent & Trademark Office Box Sequence, PO Box 2337 Arlington, VA 22202.

Rosemarie R. Wilk-Orescan, Esq.
Type or print name

Signature

July 19, 2002
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Arner et al.
Application No: 09/634,287
Filed: August 9, 2000
For: Aggrecan Degrading Metallo Proteases

Art Unit: 1644
Examiner: Patrick J. Nolan

RECEIVED

JUL 29 2002

Assistant Commissioner for Patents
Washington, DC 20231

TECH CENTER 1600/2900

Notice to Comply With Requirements for Patent Applications Containing Nucleotide
Sequence and/or Amino Acid Sequence Disclosures

Sir:

The enclosed computer readable form of the Sequence Listing is timely submitted in response to the Notice to Comply, Paper Number 12, mailed June 24, 2002, having a one month period for response. A copy of the Notice to Comply is enclosed herewith.

The Examiner has objected to the nucleotide/amino acid sequence listing as failing to comply with the requirements of CFR §1.821 because the computer readable form was damaged. Applicants have also corrected a skipped sequence error. In the originally filed sequence listing, sequence 3 was intentionally omitted.

Applicants have enclosed with this response a substitute computer readable Sequence Listing, and a paper copy of the substitute Sequence Listing.

Kindly amend the patent specification by inserting the substitute sequence listing, in its entirety, as a replacement for the sequence listing originally filed in the above identified application.

Applicants hereby certify that the newly submitted computer readable form and the written sequence listing are the same and do not contain any new matter. Support for the newly submitted sequence listings can be found on pages 47-61, and throughout the specification as originally filed. Applicants believe they are now in compliance with CFR §1.821.

Respectfully submitted,



Rosemarie R. Wilk-Orescan, Esq.
Attorney for Applicants
Reg. No. 45,220

Bristol-Myers Squibb Company
Patent Department
P.O. Box 4000
Princeton, NJ 08543-4000
609-252-3575

Date: July 19, 2002

Application 09/634,287

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

JUL 23 2002

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked-up "Raw Sequence Listing."
- 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- 7. Other: _____

RECEIVED

JUL 29 2002

TECH CENTER 1600/2900

Applicant Must Provide:

- An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216
 For CRF Submission Help, call (703) 308-4212
 PatentIn Software Program Support (SIRA)

Technical Assistance.....703-287-0200
 To Purchase PatentIn Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE